蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
查看: 1690|回复: 2
收起左侧

[GMP相关] Dr. Reddy's Laboratories 483

[复制链接]
药士
发表于 2017-10-19 17:36:31 | 显示全部楼层 |阅读模式

欢迎您注册蒲公英

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
印度Dr. Reddy's Laboratories 483
分析方法验证批数据处理(手动积分)方法和日常生产放行和稳定性数据处理方法不一致;

Dr. Reddy's Laboratories Unit 1, Srikakulam, India 6.16.17 483.pdf

262.19 KB, 下载次数: 37

回复

使用道具 举报

药士
 楼主| 发表于 2017-10-21 08:23:40 | 显示全部楼层
FDA tells Dr. Reddy's in Form 483 to keep trying with API plant in Srikakulam
by Eric Palmer | Apr 5, 2017 9:36am



A Dr. Reddy's API plant in Srikakulam, one of three named in a 2015 warning letter, has been cited with two more observations after a recent inspection by the FDA.



For the second time in about six weeks, India’s Dr. Reddy’s has been rebuffed by the FDA for its efforts to deal with the problems the agency had outlined in a warning letter two years ago.

In a filing Tuesday, India’s second-largest drugmaker said (PDF) that the FDA issued a Form 483 with two observations during a return visit to its API plant in Srikakulam. The drugmaker gave no indication of the nature of the observations but said it was addressing them.
The Srikakulam plant figured prominently in the three-plant warning letter the FDA issued to Dr. Reddy’s in 2015. It was there that investigators learned the company had a previously undisclosed quality-control lab. For years Dr. Reddy's had repeatedly tested APIs for impurities in the secret lab and not recorded failed tests, only reporting results that showed batches had met specifications.
RELATED: Dr. Reddy's blasted in warning letter for hiding existence of testing lab from FDA
The new Form 483 is a repeat of what happened in February when the company said the FDA had revisited its API plant in Miryalaguda and issued a Form 483 with three observations.
In that warning letter, the FDA cited management at the Miryalaguda plant for failing to control equipment and records to prevent testing data from being changed or destroyed, which it said employees at that plant had been doing, among other issues.

The third facility cited in the warning letter was Dr. Reddy’s Oncology Formulation manufacturing facility at Duvvada, where in 2015, inspectors raised a number of issues about the potential for contamination in the way that employees handled vials.




回复

使用道具 举报

药王
发表于 2023-1-11 18:09:34 | 显示全部楼层
看一下,谢谢分享
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

QQ|手机版|蒲公英|ouryao|蒲公英 ( 京ICP备14042168号-1 )  增值电信业务经营许可证编号:京B2-20243455  互联网药品信息服务资格证书编号:(京)-非经营性-2024-0033

GMT+8, 2025-9-6 10:30

Powered by Discuz! X3.4

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表